<DOC>
	<DOCNO>NCT02586025</DOCNO>
	<brief_summary>This Asia-Pacific regional , randomize , double-blind , Phase III , multicenter trial design evaluate treatment trastuzumab plus pertuzumab plus docetaxel compare trastuzumab plus placebo plus docetaxel chemotherapy-na√Øve patient early-stage locally advanced HER2-positive breast cancer . The anticipated treatment duration approximately 17 month .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled Study Patients With Early-Stage Locally Advanced HER2-positive Breast Cancer Evaluate Treatment With Trastuzumab + Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm invasive breast carcinoma primary tumor size &gt; 2 cm standard local assessment technique Stage presentation : earlystage ( T23 , N01 , M0 ) locally advanced ( T23 , N2 N3 , M0 ; T4 , N , M0 ) HER2positive breast cancer confirm Sponsordesignated central laboratory define 3+ score immunohistochemistry ( IHC ) &gt; 10 % immunoreactive cell HER2 gene amplification ( ratio HER2 gene signal centromere 17 signal &gt; /= 2.0 ) situ hybridization ( ISH ) A tumor sample consist tumor block eight unstained , freshly cut slide must available central laboratory HER2 test IHC ISH Known hormone receptor status ( ER PgR ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; /= 1 Baseline leave ventricular ejection fraction ( LVEF ) &gt; /= 55 % measure echocardiography ( ECHO ) ( prefer ) multiple gated acquisition ( MUGA ) scan Negative serum pregnancy test Stage IV metastatic breast cancer Inflammatory breast cancer Previous anticancer therapy radiotherapy malignancy History malignancy , except carcinoma situ cervix squamous basal cell carcinoma Concurrent anticancer treatment another investigational trial , include hormone therapy , bisphosphonate therapy , immunotherapy Major surgical procedure unrelated breast cancer within 4 week prior randomization patient fully recover Serious cardiac illness medical condition Other concurrent serious disease may interfere plan treatment , include severe pulmonary conditions/illness Any abnormality liver , kidney hematologic function laboratory test immediately prior randomization Sensitivity study medication , ingredient excipients medication , benzyl alcohol Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>